美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

康休

65.60

0.0000

成交量：- -

成交額：- -

市值：127.60億

市盈率：-1.26

高：65.60

開：65.60

低：65.60

收：65.60

52周最高：90.52

52周最低：33.13

股本：1.95億

流通股本：1.92億

量比：- -

換手率：- -

股息：0.73

股息率：1.11%

每股收益(TTM):-52.2669

每股收益(LYR):-3.5480

淨資產收益率：-77.91%

總資產收益率：-30.69%

市淨率：1.64

市盈率(LYR):-18.49

資料載入中...

總覽公司新聞資訊公告

腦機接口、AI醫療、CXO全面開花！低位佈局港股通醫療ETF（159137）或正當時

CXO行業深度報告：三重紅利共振，開啓新一輪景氣上升周期

國信證券：小核酸CXO行業景氣度持續攀升邁入臨牀兑現與商業化加速階段

陳果：春季行情未完，結構如何變化？

國聯民生證券：全球CXO行業強勢復甦 2026年有望延續高景氣

近五成生物醫藥公司業績預喜多家CXO企業表現亮眼

南方财经网

西南證券：CXO行業關注新分子的成長性與國內景氣度修復的傳導

智通港股解盤 | 擔憂地緣政治多數黃金股創歷史新高利好推動CXO全線走強

千億出海潮：中國創新藥企駛入全球深水區

國信證券：美國醫藥供應鏈新規出台關注CXO板塊投資機會

醫藥外包概念股逆市受壓康龍化成(03759)跌4.14% 機構指美生物安全法案對華CXO企業經營影響有限

港股互聯網、CXO方向有新催化！藥明生物、阿里巴巴低位反彈

每日经济新闻

美國生物科技法案未點名中國CXO！藥明生物升逾5%

每日经济新闻

醫藥外包概念普遍走高藥明生物(02269)漲6.11% 機構看好看好CXO在業績和估值端迎來雙重修復

為什麼有些頂級CEO很閒？

招銀國際：2025醫保目錄公布延續支持創新料CXO業下半年修復

一鍵佈局創新藥與CXO核心賽道恒生生物科技ETF富國蓄勢待發！

港股概念追蹤|創新藥企業績普遍增長上游CXO行業調整基本完成（附概念股）

中信建投：CXO行業調整基本完成重點關注出海能力強的CDMO企業及臨牀CRO龍頭

海納醫藥轉戰港股IPO背後：CXO依賴症、現金流失血、大客户頻變

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CXO/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"CXO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CXO\",,,,,undefined,":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CXO\",,,,,undefined,":{"symbol":"CXO","floatShares":192489259,"roa":"-30.69%","roe":"-77.91%","lyrEps":-3.548023,"shares":194506801,"dividePrice":0.725,"high":65.6,"amplitude":0,"preClose":65.6,"low":65.6,"week52Low":33.13,"pbRate":"1.64","week52High":90.52,"institutionHeld":0,"latestPrice":65.6,"eps":-52.266872,"divideRate":0.011052,"volume":0,"delay":0,"ttmEps":-52.266872,"open":65.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CXO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-01-19","symbol":"CXO","reason":null,"defaultRemindTime":1611066600000,"announcedDate":"2021-01-14","type":"delisting","dateTimestamp":1611032400000},{"market":"US","date":"2020-11-05","symbol":"CXO","amount":0.2,"defaultRemindTime":1604586600000,"name":"康休","payableDate":"2020-11-06","currency":"USD","type":"dividend","dateTimestamp":1604552400000},{"market":"US","date":"2020-10-27","symbol":"CXO","fiscalQuarterEnding":"2020/09","expectedEps":1.14,"name":null,"time":"盤後","type":"earning","dateTimestamp":1603771200000,"reportTimeType":"post","actualEps":1.43},{"market":"US","date":"2020-08-06","symbol":"CXO","amount":0.2,"defaultRemindTime":1596720600000,"name":"康休","payableDate":"2020-08-07","currency":"USD","type":"dividend","dateTimestamp":1596686400000},{"market":"US","date":"2020-07-29","symbol":"CXO","fiscalQuarterEnding":"2020/06","expectedEps":0.33,"name":null,"time":"盤後","type":"earning","dateTimestamp":1595995200000,"reportTimeType":"post","actualEps":1.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CXO\",market:\"US\",,,undefined,":[{"executeDate":"2019-02-28","recordDate":null,"paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2019-05-09","recordDate":"2019-05-10","paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2019-08-08","recordDate":"2019-08-09","paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2019-11-07","recordDate":"2019-11-08","paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2020-02-27","recordDate":"2020-02-28","paymentDate":null,"value":0.2,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CXO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CXO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CXO","date":"2021-01-15","current":-1.255097,"percent":0.244996,"low":-22.831021,"twenty":-14.937462,"median":17.448879,"eighty":43.624979,"high":142.858816,"avg":25.025998,"sd":38.430736,"marketCap":13577273687},"quantilePoints":[],"updateTime":1771725687971},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CXO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608844855","title":"腦機接口、AI醫療、CXO全面開花！低位佈局港股通醫療ETF（159137）或正當時","url":"https://stock-news.laohu8.com/highlight/detail?id=2608844855","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608844855?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 13:52","pubTimestamp":1770097920,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：杨赐","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-03/doc-inhkpkrf0233731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159137","520510","CXO","159891"],"gpt_icon":0},{"id":"2608857502","title":"CXO行業深度報告：三重紅利共振，開啓新一輪景氣上升周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608857502","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608857502?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 17:53","pubTimestamp":1770025981,"startTime":"0","endTime":"0","summary":"慧博投研近日发布研究报告，对CXO行业进行点评，其主要内容包括：CXO（医疗研发外包）作为创新药产业链的重要环节，涵盖了从药物发现到商业化生产的全流程服务。经历了2021年下半年至2024年8月的阶段性回调后，行业最差的时期已经过去。随着海外降息周期的开启、国内创新药BD出海的热潮以及新分子领域的产业升级，CXO行业正开启新一轮的高景气上行周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638803785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO"],"gpt_icon":0},{"id":"2608306028","title":"國信證券：小核酸CXO行業景氣度持續攀升 邁入臨牀兑現與商業化加速階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2608306028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608306028?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 14:30","pubTimestamp":1770013847,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，小核酸CXO作为小核酸药物产业的核心支撑，受益于技术突破与商业化加速，行业景气度持续攀升。小核酸CXO行业同步进入发展快车道，形成“研发服务-中试放大-商业化生产”的CRDMO全链条服务体系。报告中称，小核酸药物正迎来全球范围内的蓬勃发展期，已从技术验证阶段迈入临床兑现与商业化加速阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","BK0183","BK0028","CXO","002736","BK0188"],"gpt_icon":0},{"id":"2608884658","title":"陳果：春季行情未完，結構如何變化？","url":"https://stock-news.laohu8.com/highlight/detail?id=2608884658","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608884658?lang=zh_tw&edition=fundamental","pubTime":"2026-02-01 22:32","pubTimestamp":1769956320,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　受地缘局势升温、美联储主席提名落地及中美财报密集披露期等因素影响，本周市场波动加剧。　　春季行情未完，结构如何变化？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/report/2026-02-01/doc-inhkitqy8520391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PCB","CXO","BK4211"],"gpt_icon":0},{"id":"2606930347","title":"國聯民生證券：全球CXO行業強勢復甦 2026年有望延續高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2606930347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606930347?lang=zh_tw&edition=fundamental","pubTime":"2026-01-28 15:58","pubTimestamp":1769587104,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联民生证券发布研报称，全球生物科技及药企投融资活动及交易需求在2025年显著回暖，创新药新技术平台蓬勃发展，驱动CXO行业下游需求全面复苏，行业景气度有望将、在2026年延续。中国市场IND数量同比增长19%，BD交易金额同比高增，国内创新药市场活力充沛，为CXO行业提供持续动能。国内临床CRO明确拐点，泰格医药受益行业复苏中国CRO市场于2025年重回增长轨道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1564","01456","601456","161027","BK1147","BK0276","CXO"],"gpt_icon":0},{"id":"2605449493","title":"近五成生物醫藥公司業績預喜 多家CXO企業表現亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2605449493","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605449493?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 08:24","pubTimestamp":1769127883,"startTime":"0","endTime":"0","summary":"南方财经1月23日电，据中证报，截至1月22日，按照申万一级行业划分，已有逾50家生物医药企业披露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括CDMO和CRO）公司业绩表现亮眼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628152649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","CXO","LABU","399441","161726","BK4585"],"gpt_icon":0},{"id":"2603955152","title":"西南證券：CXO行業關注新分子的成長性與國內景氣度修復的傳導","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603955152?lang=zh_tw&edition=fundamental","pubTime":"2026-01-16 10:37","pubTimestamp":1768531037,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，CXO板块持续关注：1）全球市场多肽、偶联药物、寡核酸等新分子对R、D、M外包持续注入的增长动能；2）地缘风险不确定性出清后的反转与板块情绪面改善；3）国内市场景气度修复、创新药研发需求的传导；4）AI赋能的药物研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","CXO","BK0012","600369","BK0276","BK0188","BK0028"],"gpt_icon":0},{"id":"2603681308","title":"智通港股解盤 | 擔憂地緣政治多數黃金股創歷史新高 利好推動CXO全線走強","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681308?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 20:42","pubTimestamp":1768308157,"startTime":"0","endTime":"0","summary":"恒指不敢持续发力，因为还是有担忧情绪，当地时间12日，美国国务院在网站上发布信息，要求美国公民立即离开伊朗。智通1月金股——紫金黄金国际也涨超5%，同样创出了上市以来的新高。中方将坚定维护自身正当合法权益。这对中国创新药企是好消息。近日，研究服务业务首付款和总付款金额再创新高，去年合作项目的潜在里程碑付款总额高达40亿美元以上。紫金矿业巨龙铜矿项目二期全面达产后，将新增日处理20万吨矿石的产能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0052750758.USD","HK0000500386.USD","LU2045819591.USD","LU0708995583.HKD","BK1117","BK1205","SGXZ86797644.SGD","CXO","01072","BK1576","02315","BK1198","LU2213484517.USD","LU2242644610.SGD","LU2543165471.USD","BK1546","LU2125910500.SGD","LU0320764599.SGD","LU1046422090.SGD","159562","SGXZ62798434.SGD","02359","LU0593848301.USD","BK1583","02259","BK1161","BK1522","BK1141","HK0000252152.HKD","HK0000252160.HKD"],"gpt_icon":1},{"id":"2601854186","title":"千億出海潮：中國創新藥企駛入全球深水區","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854186?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BMS","CXO","BK4139","01541","BK4585","BK4526","01167","06160","ONC","00013","02509"],"gpt_icon":0},{"id":"2594286909","title":"國信證券：美國醫藥供應鏈新規出台 關注CXO板塊投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2594286909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594286909?lang=zh_tw&edition=fundamental","pubTime":"2025-12-25 09:40","pubTimestamp":1766626821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，美国国会近日通过2026财年国防授权法案，其中纳入修订版《生物安全法案》相关条款，中国创新药产业长期竞争力仍受看好。建议关注CXO板块，并留意创新药海外临床进展。国信证券主要观点如下：《生物安全法案》获参、众议院通过，关注CXO板块投资机会美国时间12月17日，美国参议院以77票赞成、20票反对的表决结果，通过2026财年国防授权法案。法案后续将提交白宫，待美国总统签署生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0183","BK1161","002736","09939","CXO","BK0276","BK1574","BK0188","BK1515","159938"],"gpt_icon":0},{"id":"2593657109","title":"醫藥外包概念股逆市受壓 康龍化成(03759)跌4.14% 機構指美生物安全法案對華CXO企業經營影響有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2593657109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593657109?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 14:06","pubTimestamp":1766383579,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股逆市受压，截至发稿，康龙化成 跌4.14%，药明生物跌3.75%，药明康德跌2.89%，昭衍新药跌2.67%，泰格医药跌2.07%，金斯瑞生物科技跌1.36%。招银国际表示，MSCI中国医疗指数2025年初至今累计上涨51.9%，跑赢MSCI中国指数24.3%。近期，医药板块有所回调。政策端方面，《生物安全法案》虽已签署生效，但鉴于其未波及Medicaid和Medicare的采购且对关联方定义明确，以及中国CXO美国行政机构收入占比较小，该机构预计该法案对中国CXO企业实质经营影响有限。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0327786744.USD","300759","LU0320764599.SGD","LU0823426308.USD","BK0216","LU0140636845.USD","LU0326950275.SGD","LU0359201612.USD","LU0359202008.SGD","LU0819121731.USD","LU3063872942.SGD","SG9999002562.SGD","BK1583","LU2039709279.SGD","02269","LU0708995583.HKD","BK1574","LU1720050803.USD","BK1161","09939","LU0417516902.SGD","03347","01548","BK1576","LU0456846285.SGD","LU0348825331.USD","LU0572944931.SGD","LU0348735423.USD","LU0417516738.SGD","CXO","LU0516423174.USD","02359","HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","LU0516423091.SGD","BK1610","LU1242518931.SGD","BK1589","159938","03759","LU0051755006.USD","06127","SG9999002463.SGD","LU2125910500.SGD","LU0516422440.USD","HK0000306701.USD","LU1046422090.SGD","BK1141","LU1880383366.USD"],"gpt_icon":0},{"id":"2592134914","title":"港股互聯網、CXO方向有新催化！藥明生物、阿里巴巴低位反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=2592134914","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592134914?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 11:17","pubTimestamp":1766114256,"startTime":"0","endTime":"0","summary":"港股科技两大核心资产——互联网、创新药低位反弹，港股通科技ETF基金涨1.5%，成分股药明生物涨超6%，药明合联涨超4%，腾讯、美团、阿里巴巴小幅上涨。相比恒生科技，国证港股通科技减配消费零售，增配了医药生物，以及硬件设备等，同时单一个股权重上限较高，更聚焦互联网+CXO龙头，因此指数弹性更大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121911180097a07b68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121911180097a07b68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09988","LU0072462343.USD","BK4533","BK4588","BK4502","LU1051768304.USD","BK4220","LU2226246903.HKD","BK4614","BK4505","LU0501845795.SGD","CXO","LU0918141705.HKD","BK4534","LU0106959298.USD","LU1769817179.HKD","LU1048588211.SGD","BK4548","LU0821914370.USD","LU1769817096.USD","IE00BF5LJ272.USD","BK4531","LU1267930227.SGD","ALBmain","IE00BFMHRM44.USD","BK4565","LU0738911758.USD","LU1046422090.SGD","LU1152091754.HKD","BK4558","LU1242518857.USD","LU0651947912.USD","LU0251143458.SGD","LU0880133367.SGD","LU1105468828.SGD","LU0328353924.USD","BABA","LU0553294199.USD","BK4538","IE00B0JY6N72.USD","LU0047713382.USD","BK4524","LU1242518931.SGD","LU2148611432.USD","LU1515016050.SGD","LU0052756011.USD","BK4579","BK4503","LU1003077747.HKD","LU1008478684.HKD"],"gpt_icon":1},{"id":"2592310861","title":"美國生物科技法案未點名中國CXO！藥明生物升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592310861","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592310861?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 10:53","pubTimestamp":1766112795,"startTime":"0","endTime":"0","summary":"【美国生物科技法案未点名中国CXO！药明生物涨超5%】12月19日，港股科技板块展开反弹修复，恒生生物科技、港股通科技指数涨幅领先，两大指数共同的成分股药明生物涨超5%，药明合联涨超4%，信达生物、康方生物涨超2%。消息面上，美国当地时间12月18日，2026财年国防授权法案（2026NDAA）获通过，新版本生物安全法未具体点名任何一家公司，显著利好此前备受安全法案煎熬的中国CXO公司（药明康德和药明生物等）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193596567879.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596567879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159837","LU3063872942.SGD","LU0823426480.USD","LU0516423091.SGD","LU0417516902.SGD","CXO","LU0516422440.USD","IE00B0JY6N72.USD","LU0181495838.USD","LU1688375341.USD","LU0823426308.USD","LU0856984785.SGD","LU0307460666.USD","LU1880383366.USD","LU0043850808.USD","LU0516422366.SGD","SG9999002463.SGD","LU0708995583.HKD","LU1794554557.SGD","LU0819121731.USD","LU1720050803.USD","LU0456846285.SGD","LU0052750758.USD","BK1576","LU0320764599.SGD","BK1610","LU0348825331.USD","LU0039217434.USD","BK1589","LU0516423174.USD","LU1242518931.SGD","SG9999002562.SGD","02269","LU0417516738.SGD","LU0456827905.SGD","LU0327786744.USD","LU0588546209.SGD","LU0572944931.SGD","BK1141","LU0979878070.USD","LU0359201612.USD","LU0359202008.SGD","LU0348735423.USD","LU0516422952.EUR","LU2039709279.SGD","LU1242518857.USD","BK1521","LU0140636845.USD","LU0051755006.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2592139047","title":"醫藥外包概念普遍走高 藥明生物(02269)漲6.11% 機構看好看好CXO在業績和估值端迎來雙重修復","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139047","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592139047?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 10:26","pubTimestamp":1766111188,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念普遍走高，药明生物 涨6.11%，凯莱英升5.52%，康龙化成升4.69%，泰格医药升3.8%，维亚生物升3.72%，药明康德涨3.32%。世纪证券此前研报指出，本周NDAA法案落地，地缘风险趋于缓和。CXO业绩和新增订单开始好转，本周市场开始关注临床前安评试验资产食蟹猴。该机构认为CXO作为创新药产业链上游，行业经历过完整周期，有望受益于国产创新药竞争力提升带来的景气度回升，看好CXO在业绩和估值端迎来双重修复。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66afc1ba6d0078bbc724c4259409298b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","LU0979878070.USD","LU0348735423.USD","159938","BK1191","01873","LU1880383366.USD","LU2125910500.SGD","LU0052750758.USD","BK1574","LU0181495838.USD","03347","02359","BK1161","LU0051755006.USD","LU3063872942.SGD","BK1576","02269","LU0516422952.EUR","LU1720050803.USD","LU1242518931.SGD","LU0516422440.USD","09939","LU0140636845.USD","SG9999002562.SGD","BK1521","BK1589","LU0320764599.SGD","LU2045819591.USD","LU0456827905.SGD","LU0823426480.USD","LU1794554557.SGD","LU0516423174.USD","BK1610","LU1046422090.SGD","LU0516423091.SGD","SG9999002463.SGD","BK1583","IE00B0JY6N72.USD","LU0039217434.USD","LU0359201612.USD","06821","LU0708995583.HKD","LU2242644610.SGD","LU0417516902.SGD","LU0516422366.SGD","LU0348825331.USD","CXO","LU0819121731.USD","LU0043850808.USD"],"gpt_icon":0},{"id":"2590653902","title":"為什麼有些頂級CEO很閒？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590653902","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590653902?lang=zh_tw&edition=fundamental","pubTime":"2025-12-10 18:07","pubTimestamp":1765361220,"startTime":"0","endTime":"0","summary":"我也见过更多相反样子的企业家：那些把自己逼疯、同时也把团队逼疯，最终业绩却依然平平的CEO。为什么顶级CEO敢“闲”下来？回到我的朋友，这位厉害的年轻CEO看似“很闲”，实则是在做高杠杆的事情。我观察到，顶级CEO的日程表中，都会神圣不可侵犯地预留出“无干扰时间”。平台型/高科技轻资产：更依赖顶层架构设计和人才密度，CEO更应像一位“总架构师”，而非“工头”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656136868&idx=1&sn=469d3631fb8da8d780e1e1f4c5235692&chksm=671b275db4bd1a32a8433d9f74e8f6be5eb9e926da6c9bb4c9cf83b1d53b3e3dd6ed55a6b3a5&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["CXO"],"gpt_icon":0},{"id":"2590393913","title":"招銀國際：2025醫保目錄公布延續支持創新 料CXO業下半年修復","url":"https://stock-news.laohu8.com/highlight/detail?id=2590393913","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590393913?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 10:03","pubTimestamp":1765245827,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，2025年版基本医保目录以及首版商保目录发布，延续支持创新，料CXO行业有望在下半年迎来业绩修复。推荐买入三生制药(01530)、固生堂(02273)、药明合联(02268)、巨子生物(02367)、信达生物(01801)、中国生物制药(01177)。报告表示，多家企业的核心创新品种获纳入医保。该行认为，宏观环境及老龄化的挑战下，医保收支压力仍在，关注国家集采续约。尽管首版商保目录短期对于产品销售的拉动有限，由于商业保险的规模不大，认为商保目录的意义重大，或将开启中国商业医疗保险扩容的道路，成为中国多元化支付体系发展开端。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0455707207.USD","HK0000165453.HKD","CXO","BK1593","BK1515","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","02268","LU2097828805.USD","LU2328871848.SGD","02367","BK1219","LU0502904849.HKD","BK1583","01530","LU2488822045.USD","01801","LU2097828631.EUR","BK1207","BK1141","LU2097828714.EUR","BK1191","BK1589","LU1969619763.USD","LU2097828474.EUR","02273","BK1161","BK1521","LU2097828557.USD","SG9999004311.SGD","SG9999014674.SGD","IE00BZ08YS42.EUR","01177","LU2242644610.SGD"],"gpt_icon":0},{"id":"2586206538","title":"一鍵佈局創新藥與CXO核心賽道 恒生生物科技ETF富國蓄勢待發！","url":"https://stock-news.laohu8.com/highlight/detail?id=2586206538","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586206538?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 14:33","pubTimestamp":1764311580,"startTime":"0","endTime":"0","summary":"今年以来，港股医药板块持续吸引市场目光。Wind数据显示，截至11月24日，南向资金近一年净买入医疗保健业超1600亿元，净买入额在12个恒生一级行业中排名第三。在此背景下，富国基金拟于12月1日正式发行恒生生物科技ETF富国，为投资者提供一键布局港股生物科技龙头的高效投资工具。此次恒生生物科技ETF富国的推出，有望成为投资者布局港股医药投资机遇的有力工具。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2025-11-28/doc-infyxwfe8322416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["513280","BK1574","CXO","06978","BK1161","159992"],"gpt_icon":0},{"id":"2585363594","title":"港股概念追蹤|創新藥企業績普遍增長  上游CXO行業調整基本完成（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2585363594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585363594?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 08:12","pubTimestamp":1763943133,"startTime":"0","endTime":"0","summary":"国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","06978","LU0516423091.SGD","BK1191","LU0588546209.SGD","BK1161","LU3063872942.SGD","LU0823426480.USD","159992","06821","LU0348825331.USD","LU0417516738.SGD","LU0823426308.USD","LU1242518931.SGD","BK1583","LU1794554557.SGD","BK1141","LU2125910500.SGD","LU0039217434.USD","BK1589","BK1521","02269","LU0979878070.USD","LU0052750758.USD","LU1688375341.USD","SG9999002562.SGD","LU0181495838.USD","LU0456827905.SGD","LU0516422366.SGD","LU0819121731.USD","SG9999002463.SGD","BK1576","LU0359202008.SGD","IE00B0JY6N72.USD","LU0326950275.SGD","LU0140636845.USD","LU0708995583.HKD","LU1242518857.USD","LU2242644610.SGD","LU0051755006.USD","BK1574","LU1046422090.SGD","LU1880383366.USD","LU0043850808.USD","LU2045819591.USD","CXO","BK1610","LU0417516902.SGD","LU2039709279.SGD","LU0348735423.USD"],"gpt_icon":0},{"id":"2585435821","title":"中信建投：CXO行業調整基本完成 重點關注出海能力強的CDMO企業及臨牀CRO龍頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585435821?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 07:36","pubTimestamp":1763940962,"startTime":"0","endTime":"0","summary":"CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。从国际比较优势看，中国具备人口与内需优势、制造与供应链优势，同时创新能力快速提升，中国资产出海数量也持续提升。2025年下半年我们重点关注的是药品和耗材集采政策优化、多元化支付及医疗服务价格改革。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDMO","BK0276","BK4139","601066","CXO"],"gpt_icon":0},{"id":"2585448396","title":"海納醫藥轉戰港股IPO背後：CXO依賴症、現金流失血、大客户頻變","url":"https://stock-news.laohu8.com/highlight/detail?id=2585448396","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585448396?lang=zh_tw&edition=fundamental","pubTime":"2025-11-23 15:28","pubTimestamp":1763882880,"startTime":"0","endTime":"0","summary":"　　冲刺A股创业板折戟、被上市公司成都先导并购未果后，近日南京海纳医药科技股份有限公司递交招股书转道港股市场，开启三年内的第三次资本化尝试。　　证券之星注意到，这家号称“药物技术转移CXO服务排名第二”的公司，正面临经营性现金流转负、应收账款激增，毛利率承压的多重考验。这背后，海纳医药高度依赖CXO业务，陷入“增收不增利”困境，频繁变动的大客户更凸显业务结构的不稳定性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-11-23/doc-infykswe4862812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","BK1574","BK1161","09939","BK1515","159399","159938"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}